|

Dasatinib Clinical Trials

17 actively recruiting trials across 7 locations

▼ -2 trials since July 2026

Also known as: 6-MP, Asparaginase, BMS 354825, BMS-354825, BMS354825 +14 more

Pipeline

Early 1: 2Phase 1: 1Phase 2: 10Phase 4: 2Phase 1/2: 1Phase 2/3: 1

Top Sponsors

  • St. Jude Children's Research Hospital2
  • Mayo Clinic2
  • Wei Zhao1
  • University of Chicago1
  • Princess Maxima Center for Pediatric Oncology1

Indications

  • Cancer17
  • Acute Lymphoblastic Leukemia4
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive1
  • Recurrent Multiple Myeloma1
  • Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory1

Other7 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Phase 2
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Phase 4
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Phase 2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Phase 1/2
Newly-diagnosed Pediatric T-cell ALL Protocol
Phase 2/3
Pilot Trial for Treatment of Recurrent Glioblastoma
Early 1
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Phase 2

Birmingham, Alabama2 trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 2
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

University of Alabama/Children's of Alabama

Phase 2

Chicago, Illinois2 trials

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

University of Chicago Comprehensive Cancer Center

Phase 1
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

University of Chicago Medical Center

Phase 2

Rochester, Minnesota2 trials

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic in Rochester

Phase 2
Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease

Mayo Clinic in Rochester

Early 1

San Diego, California1 trial

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Rady Children's Hospital

Phase 2

Ann Arbor, Michigan1 trial

Asciminib Roll-over Study

Michigan Med University of Michigan

Phase 4

Detroit, Michigan1 trial

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

The Barbara Ann Karmanos Cancer Institute

Phase 2

Charlotte, North Carolina1 trial

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Novant Health Presbyterian Hemby Children's Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.